Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627450 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL113727 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL899138 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL10998172 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL875411 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL125343 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL3454563 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL20193278 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 | |
| SCHEMBL8904061 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 | |
| SCHEMBL20580710 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999043287-A2 | PHOSPHATE-BASED DENDRIMERS FOR BIOASSAYS | BIOTRACES, INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-2025151495-A1 | ALLELE-SPECIFIC KNOCKDOWN OF GENE EXPRESSION | UNIVERSITY OF MASSACHUSETTS (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024127215-A2 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240189410-A1 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | PFIZER (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240100132-A1 | MODULATION OF AAV-BASED GENE EXPRESSION | PREVAIL THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024036186-A2 | IDENTIFICATION OF ALLELE-SPECIFIC TARGET SEQUENCES FOR C9ORF72 | THE UNIVERSITY OF MASSACHUSETTS (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4281561-A1 | MODULATION OF AAV-BASED GENE EXPRESSION | Prevail Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11827886-B2 | Compositions and methods for modulating dysferlin expression | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-28 | — | — | US | disclosed |
| CN-110753756-B | Immunomodulatory polynucleotides and uses thereof | 华普生物技术(河北)股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | CHANGCHUN HUAPU BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20040053880-A1 | Nucleic acid compositions for stimulating immune responses | COLEY PHARMACEUTICAL GROUP, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004016805-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2003-10-30 | — | — | US | disclosed |
| US-6472521-B1 | Oligonucleotides for the inhibition of human eg5 expression | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20010021772-A1 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | US | disclosed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999043287-A2 | PHOSPHATE-BASED DENDRIMERS FOR BIOASSAYS | BIOTRACES, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5000874-A | Concentrated compositions and their use as stabilizers for peroxide-containing alkaline liquors | SANDOZ LTD. (CH) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | TLR3, TLR9, CD47 | MEN1 2463/4885KMT2A 2203/4885TSHR 3722/4885 |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLN, POLR2H | MEN1 4013/4885KMT2A 1528/4885TSHR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.